GlaxoSmithKline And Theravance Announce Expansion Of The Horizon Programme With Start Of Large Phase 2B Study Of LABA In COPD Patients
Mar 3rd 2008Drug InformationClinical Trials
GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced the expansion of the Horizon programme into development of a next-generation combination treatment for patients with chronic obstructive pulmonary disorder (COPD). A large Phase 2b COPD dose-optimisation study with the lead long-acting beta agonist (LABA) GW642444 (’444) has commenced, with screening of the first patient undertaken.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
